Print

Breast cancer outcomes improved with CDK4/6 inhibitor treatment

https://www.facingourrisk.org/XRAY/MBC-outcomes-with-CDK-inhibitor-Ibrance-palbociclib
Full article: https://pubmed.ncbi.nlm.nih.gov/35552673/

A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following organizations have resources related to breast cancer. 

The following studies look at treatment for people with metastatic ER-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 

 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.